Working… Menu

Vitamin C for Severe Thermal Injuries

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01587261
Recruitment Status : Withdrawn (This potential study was held up at the level of the FDA as they wouldn't approve and IND for the dose of vitamin C we wanted to use.)
First Posted : April 30, 2012
Last Update Posted : March 6, 2019
Information provided by (Responsible Party):
University of Texas Southwestern Medical Center

Brief Summary:
Animal and human data have supported the notion that administration of large doses of Vitamin C has beneficial effects on those subjects suffering from large burns. This effect may be due, in part, to the antioxidant and free-radical-scavenging properties of Vitamin C. These studies have demonstrated an improvement in urine output during resuscitation and reduced need for fluid volumes during resuscitation. In turn, these subjects demonstrated a reduction of wound edema, improved respiratory status (demonstrated by improvements in P:F ratios and reduced ventilator days), and no differences in terms of the possible complications of high-dose vitamin C administration between standard and treatment groups. The purpose of this study is to prospectively determine if Vitamin C can be safely used as an adjunctive treatment for patients suffering severe thermal injuries. High-dose vitamin C administered at a dose of 66mg/kg/hr during the acute phase of severe burn injuries will reduce fluid requirements in the first 48 hours after injury.

Condition or disease Intervention/treatment Phase
Severe Thermal Injury, Greater Than 20% TBSA Drug: Vitamin C Drug: Placebo Phase 2

Detailed Description:
Subjects presenting within 6 hours of a severe thermal injury, defined as greater than 20% of their total body surface area, or their family members will be approached on admission to Parkland Memorial Hospital and informed of the study. Those electing to participate in the study will be randomized to receive either high-dose vitamin C (66mg/kg/hr for the first 24 hours, this dosage is based on prior human studies) in addition to the standard resuscitation algorithm (as per the Parkland Formula) or to a control group receiving only the standard resuscitation algorithm. These subjects will then be followed during their hospital course for fluid requirements, urine output, infectious complication rates, liver/renal failure rates, abdominal compartment syndrome rates, and outcomes such as ICU days, total hospital days, and mortality. All adverse events will be monitored by a data safety monitoring board. Currently this is a planned pilot study with a future multi-center study planned based on the results of the pilot. These studies will help determine if high-dose vitamin C can be a safe adjunct to acute fluid resuscitation in severely burned patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Prospective Placebo-Controlled Double-Blinded Trial for High-Dose Vitamin C Administration During the Acute Resuscitative Phase of Severe Thermal Injuries
Estimated Study Start Date : June 2017
Estimated Primary Completion Date : June 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Burns Vitamin C

Arm Intervention/treatment
Placebo Comparator: Placebo
Victims of severe thermal injury receiving placebo Lactated Ringers solution for the first 24 hours
Drug: Placebo
Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
Other Name: LR

Experimental: Vitamin C
Victims of severe thermal injury receiving high-dose vitamin C 66 mg/kg/hr for the first 24 hours
Drug: Vitamin C
Treatment Group will receive a dose of 66 mg/kg/hr of ascorbic acid injection for 24 hours after injury
Other Name: High Dose Ascorbic Acid

Primary Outcome Measures :
  1. Fluid Volume Requirements during the resuscitative phase after severe burn [ Time Frame: 24 hours ]
    Primary Outcome is to reduce fluid outcome requirements within the first 24 hours after severe thermal injury

Secondary Outcome Measures :
  1. Days of Ventilator Support Required [ Time Frame: Hospital Course, estimated 6 weeks ]
    Comparisons between cohorts as to the number of days of ventilator support will be measured

  2. Incidence of Abdominal Compartment Syndrome [ Time Frame: Hospital Course, estimated 6 weeks ]
  3. Complication and infection rates in the Vitamin C group [ Time Frame: Hospital Course, estimated 6 weeks ]
  4. Incidence of Renal Failure [ Time Frame: Hospital Course, estimated 6 weeks ]
    Incidence of renal failure between cohorts will be measured

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects presenting with second and/or third degree burns exceeding 20% total body surface area but not greater than 75% TBSA
  2. Age between 18 and 65 years of age
  3. Subject has provided full written informed consent prior to the performance of any study-related treatment or procedure

Exclusion Criteria:

  1. Subjects presenting more than 6 hours from the estimated time of injury
  2. Known inclusion in another interventional clinical trial
  3. Subjects with known significant comorbidities (Congestive Heart Failure, Myocardial Infarction within 6 months of admission, Chronic Obstructive Pulmonary Disease, Chronic Kidney Disease or Renal Impairment)
  4. Pregnant Subjects
  5. Prisoners or Subjects Under Arrest
  6. Subjects younger than 18 years of age or older than 65 years of age
  7. Subjects with Baux Scores (Age plus % TBSA) greater than 120 (describing a non-survivable injury)
  8. Subjects with any known allergy to components included in injectable ascorbic acid
  9. Subjects with significant trauma burden (ISS > 15), including any open fracture, intracranial hemorrhage, or significant intra-abdominal injury.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01587261

Layout table for location information
United States, Texas
Parkland Memorial Hospital
Dallas, Texas, United States, 75235
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Layout table for investigator information
Principal Investigator: Kareem R AbdelFattah, MD UT-Southwestern
Study Director: Victoria Warren, RN UT-Southwestern
Layout table for additonal information
Responsible Party: University of Texas Southwestern Medical Center Identifier: NCT01587261    
Other Study ID Numbers: KRA2012
First Posted: April 30, 2012    Key Record Dates
Last Update Posted: March 6, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Texas Southwestern Medical Center:
Vitamin C
Thermal Injury
Fluid Resuscitation
Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries
Ascorbic Acid
Growth Substances
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Protective Agents